Genome-wide_JJ detection_NN of_IN tissue-specific_JJ alternative_NN splicing_VBG in_IN the_DT human_JJ transcriptome_NN We_PP have_VBP developed_VBN an_DT automated_JJ method_NN for_IN discovering_VBG tissue-specific_JJ regulation_NN of_IN alternative_NN splicing_VBG through_IN a_DT genome-wide_JJ analysis_NN of_IN expressed_VBN sequence_NN tags_NNS (_( ESTs_NN )_) ._SENT Using_VBG this_DT approach_NN ,_, we_PP have_VBP identified_VBN 667_CD tissue-specific_JJ alternative_JJ splice_NN forms_NNS of_IN human_JJ genes_NNS ._SENT We_PP validated_VBD our_PP$ muscle-specific_JJ and_CC brain-specific_JJ splice_NN forms_NNS for_IN known_JJ genes_NNS ._SENT A_DT high_JJ fraction_NN (_( 8_CD /10_CD )_) were_VBD reported_VBN to_TO have_VB a_DT matching_VBG tissue_NN specificity_NN by_IN independent_JJ studies_NNS in_IN the_DT published_VBN literature_NN ._SENT The_DT number_NN of_IN tissue-specific_JJ alternative_JJ splice_NN forms_NNS is_VBZ highest_JJS in_IN brain_NN ,_, while_IN eye_retina_NN ,_, muscle_NN ,_, skin_NN ,_, testis_NN and_CC lymph_NN have_VBP the_DT greatest_JJS enrichment_NN of_IN tissue-specific_JJ splicing_VBG ._SENT Overall_RB ,_, 10_CD --_: 30_CD %_NN of_IN human_NN alternatively_RB spliced_VBD genes_NNS in_IN our_PP$ data_NNS show_VBP evidence_NN of_IN tissue-specific_JJ splice_NN forms_NNS ._SENT Seventy-eight_JJ percent_NN of_IN our_PP$ tissue-specific_JJ alternative_NN splices_NNS appear_VBP to_TO be_VB novel_JJ discoveries_NNS ._SENT We_PP present_VBP bioinformatics_NN analysis_NN of_IN several_JJ tissue-specific_JJ splice_NN forms_NNS ,_, including_VBG automated_JJ protein_NN isoform_NN sequence_NN and_CC domain_NN prediction_NN ,_, showing_VBG how_WRB our_PP$ data_NNS can_MD provide_VB valuable_JJ insights_NNS into_IN gene_NN function_NN in_IN different_JJ tissues_NNS ._SENT For_IN example_NN ,_, we_PP have_VBP discovered_VBN a_DT novel_JJ kidney-specific_JJ alternative_NN splice_NN form_NN of_IN the_DT WNK1_NP gene_NN ,_, which_WDT appears_VBZ to_TO specifically_RB disrupt_VB its_PP$ N-terminal_JJ kinase_NN domain_NN and_CC may_MD play_VB a_DT role_NN in_IN PHAII_NP hypertension_NN ._SENT Our_PP$ database_NN greatly_RB expands_VBZ knowledge_NN of_IN tissue-specific_JJ alternative_NN splicing_VBG and_CC provides_VBZ a_DT comprehensive_JJ dataset_NN for_IN investigating_VBG its_PP$ functional_JJ roles_NNS and_CC regulation_NN in_IN different_JJ human_JJ tissues_NNS ._SENT Recently_RB ,_, there_EX has_VBZ been_VBN growing_VBG interest_NN in_IN alternative_NN splicing_VBG as_IN a_DT mechanism_NN for_IN expanding_VBG the_DT repertoire_NN of_IN gene_NN functions_NNS ._SENT Different_JJ combinations_NNS of_IN exons_NNS can_MD be_VB spliced_VBN together_RB to_TO produce_VB different_JJ mRNA_NN isoforms_NNS of_IN a_DT gene_NN ,_, encoding_VBG structurally_RB and_CC functionally_RB different_JJ protein_NN products_NNS ._SENT The_DT discovery_NN from_IN large-scale_JJ genomics_NN studies_NNS that_IN alternative_JJ splicing_VBG may_MD occur_VB in_IN a_DT very_RB large_JJ fraction_NN of_IN human_JJ genes_NNS (_( 35_CD --_: 59_CD %_NN )_) suggests_VBZ a_DT major_JJ role_NN for_IN alternative_NN splicing_VBG in_IN the_DT production_NN of_IN functional_JJ complexity_NN in_IN the_DT human_JJ genome_NN (_( --_: )_) ._SENT This_DT hypothesis_NN implies_VBZ extensive_JJ regulation_NN of_IN alternative_NN splicing_VBG ._SENT Alternative_JJ splicing_VBG can_MD display_VB strong_JJ specificity_NN to_TO a_DT particular_JJ tissue_NN or_CC developmental_JJ stage_NN (_( ,_, )_) ,_, modulating_VBG the_DT functional_JJ characteristics_NNS of_IN protein_NN isoforms_NNS in_IN specific_JJ tissues_NNS ._SENT It_PP has_VBZ also_RB been_VBN estimated_VBN that_IN similar15_JJ %_NN of_IN disease-causing_VBG mutations_NNS in_IN human_JJ genes_NNS involve_VBP misregulation_NN of_IN alternative_NN splicing_VBG and_CC errors_NNS in_IN mRNA_NN processing_NN have_VBP been_VBN associated_VBN with_IN cancer_NN and_CC other_JJ human_JJ diseases_NNS (_( --_: )_) ._SENT Despite_IN growing_VBG interest_NN in_IN how_WRB alternative_NN splicing_VBG is_VBZ regulated_JJ (_( ,_, --_: )_) ,_, relatively_RB little_RB is_VBZ known_VBN about_IN tissue-specific_JJ alternative_NN splicing_VBG and_CC its_PP$ regulation_NN ,_, especially_RB when_WRB compared_VBN with_IN the_DT sheer_JJ volume_NN of_IN information_NN known_VBN about_IN other_JJ mechanisms_NNS of_IN functional_JJ control_NN such_JJ as_IN transcriptional_JJ regulation_NN ._SENT For_IN example_NN ,_, tissue_NN specificities_NNS for_IN only_RB a_DT small_JJ number_NN of_IN alternatively_RB spliced_VBN genes_NNS (_( about_RB 50_CD )_) are_VBP listed_VBN in_IN current_JJ alternative_NN splicing_VBG databases_NNS (_( ,_, )_) ._SENT If_IN alternative_JJ splicing_VBG plays_NNS as_IN large_JJ and_CC important_JJ a_DT role_NN in_IN gene_NN function_NN regulation_NN as_IN recent_JJ genomics_NNS studies_NNS suggest_VBP ,_, much_RB more_JJR information_NN is_VBZ needed_VBN ._SENT There_EX are_VBP many_JJ questions_NNS that_WDT need_VBP to_TO be_VB answered_VBN ._SENT What_WP fraction_NN of_IN alternative_NN splicing_VBG is_VBZ tissue-specific_JJ ?_SENT What_WP proportion_NN of_IN tissue-specific_NN splicing_VBG is_VBZ associated_VBN with_IN gross_JJ subdivisions_NNS of_IN tissues_NNS (_( such_JJ as_IN an_DT entire_JJ organ_NN like_IN the_DT brain_NN )_) versus_CC very_RB specific_JJ cell_NN types_NNS and_CC developmental_JJ states_NNS ?_SENT How_WRB can_MD we_PP efficiently_RB identify_VB the_DT complete_JJ regulatory_JJ machinery_NN controlling_VBG tissue_NN specificity_NN ?_SENT What_WP are_VBP the_DT regulatory_JJ factors_NNS that_WDT mediate_VBP this_DT process_NN and_CC what_WP are_VBP the_DT control_NN sites_NNS that_WDT they_PP recognize_VBP ?_SENT What_WP are_VBP the_DT functional_JJ consequences_NNS of_IN these_DT alternative_NN splicing_VBG events_NNS ?_SENT To_TO answer_VB any_DT of_IN these_DT questions_NNS ,_, one_CD essential_JJ prerequisite_NN is_VBZ large-scale_JJ discovery_NN and_CC characterization_NN of_IN tissue-specific_JJ alternative_NN splicing_VBG ,_, for_IN example_NN by_IN microarray_NN analysis_NN (_( --_: )_) ._SENT This_DT is_VBZ needed_VBN both_CC to_TO provide_VB biologists_NNS with_IN information_NN on_RP whether_IN '_'' their_PP$ gene_NN '_'' is_VBZ alternatively_RB spliced_VBN in_IN a_DT tissue-specific_JJ manner_NN (_( enabling_VBG them_PP to_TO study_VB its_PP$ functional_JJ consequences_NNS )_) and_CC to_TO give_VB splice_NN regulation_NN researchers_NNS a_DT big_JJ enough_JJ dataset_NN to_TO study_VB mechanisms_NNS of_IN splice_NN regulation_NN in_IN many_JJ genes_NNS and_CC tissues_NNS ._SENT One_CD possible_JJ approach_NN is_VBZ to_TO use_VB genomics_NN datasets_NNS such_JJ as_IN expressed_VBN sequence_NN tags_NNS (_( ESTs_NN )_) for_IN large-scale_JJ analysis_NN of_IN tissue_NN specificity_NN ._SENT This_DT poses_VBZ two_CD challenges_NNS ._SENT Although_IN the_DT EST_JJ database_NN provides_VBZ some_DT information_NN about_IN tissue_NN source_NN ,_, these_DT data_NNS are_VBP incomplete_JJ and_CC inconsistent_JJ ._SENT Thus_RB ,_, a_DT consistent_JJ tissue_NN classification_NN of_IN this_DT large_JJ dataset_NN is_VBZ needed_VBN to_TO enable_VB detection_NN of_IN tissue_NN specificity_NN ._SENT Much_RB more_RBR importantly_RB ,_, interpretation_NN of_IN these_DT data_NN requires_VBZ filtering_VBG for_IN statistical_JJ significance_NN ._SENT EST_NP data_NNS often_RB have_VBP poor_JJ coverage_NN (_( i.e._FW only_RB a_DT small_JJ number_NN of_IN ESTs_NN from_IN a_DT given_VBN tissue_NN for_IN a_DT region_NN of_IN interest_NN in_IN a_DT gene_NN )_) and_CC many_JJ sampling_VBG artifacts_NNS ._SENT For_IN example_NN ,_, there_EX can_MD be_VB dramatically_RB different_JJ numbers_NNS of_IN ESTs_NNS from_IN different_JJ libraries_NNS or_CC tissues_NNS ,_, creating_VBG sample_NN bias_NN ._SENT This_DT could_MD give_VB the_DT erroneous_JJ impression_NN that_IN a_DT given_VBN splice_NN form_NN is_VBZ specific_JJ to_TO one_CD tissue_NN (_( simply_RB because_IN many_JJ ESTs_NNS for_IN this_DT gene_NN have_VBP been_VBN sequenced_VBN from_IN that_DT tissue_NN and_CC few_JJ from_IN other_JJ tissues_NNS )_) ._SENT We_PP have_VBP sought_VBN to_TO address_VB both_CC these_DT problems_NNS ._SENT In_IN this_DT paper_NN we_PP present_VBP an_DT automatic_JJ method_NN to_TO detect_VB tissue-specific_JJ alternative_NN splicing_VBG events_NNS using_VBG EST_JJ and_CC genomic_JJ sequences_NNS ._SENT After_IN constructing_VBG a_DT tissue_NN list_NN of_IN 46_CD human_JJ tissues_NNS with_IN 2_CD million_CD human_JJ ESTs_NNS ,_, we_PP generated_VBD a_DT database_NN of_IN novel_JJ human_JJ alternative_NN splices_NNS that_WDT is_VBZ four_CD times_NNS larger_JJR than_IN our_PP$ previous_JJ report_NN and_CC used_VBN Bayesian_JJ statistics_NNS to_TO compare_VB the_DT relative_JJ abundance_NN of_IN every_DT pair_NN of_IN alternative_JJ splices_NNS in_IN these_DT tissues_NNS ._SENT Using_VBG several_JJ statistical_JJ criteria_NNS for_IN tissue_NN specificity_NN ,_, we_PP have_VBP identified_VBN 667_CD tissue-specific_JJ alternative_NN splicing_VBG relationships_NNS and_CC analyzed_VBD their_PP$ distribution_NN in_IN human_JJ tissues_NNS ._SENT We_PP have_VBP validated_VBN our_PP$ results_NNS by_IN comparison_NN with_IN independent_JJ studies_NNS ._SENT This_DT genome-wide_JJ analysis_NN of_IN tissue_NN specificity_NN of_IN alternative_JJ splicing_VBG will_MD be_VB made_VBN available_JJ as_IN a_DT part_NN of_IN the_DT Human_NP Alternative_NP Splicing_NP Database_NP ,_, to_TO provide_VB a_DT useful_JJ resource_NN to_TO study_VB the_DT tissue-specific_JJ functions_NNS of_IN transcripts_NNS and_CC the_DT association_NN of_IN tissue-specific_JJ variants_NNS with_IN human_JJ diseases_NNS ._SENT Data_NNS sources_NNS |_SYM Our_JJ analysis_NN is_VBZ based_VBN on_IN three_CD sources_NNS of_IN data_NNS :_: human_JJ genomic_JJ sequence_NN assemblies_NNS ,_, human_JJ ESTs_NN from_IN the_DT UniGene_NP database_NN and_CC human_JJ EST_JJ library_NN information_NN ._SENT Human_JJ genomic_JJ assembly_NN sequences_NNS (_( accession_VB no_RB ._SENT NT_XXXX_NP )_) and_CC '_'' draft_NN '_POS BAC_NP clone_NN sequences_NNS (_( accession_NN nos_NNS ACXXXX_NP ,_, ALXXXXX_NP )_) were_VBD downloaded_VBN from_IN NCBI_NP (_( and_CC )_) ._SENT Human_JJ ESTs_NN and_CC library_NN information_NN were_VBD downloaded_VBN from_IN UniGene_NP ._SENT Additional_JJ EST_JJ library_NN information_NN about_IN human_JJ tissue_NN sources_NNS was_VBD obtained_VBN from_IN the_DT NCBI_NP Library_NP Browser_NP ,_, downloaded_VBN from_IN ._SENT The_DT work_NN described_VBN in_IN this_DT paper_NN is_VBZ based_VBN on_IN the_DT January_NP 2002_CD release_NN of_IN the_DT human_JJ genome_NN and_CC UniGene_JJ data_NNS ._SENT Library_NN classification_NN |_SYM Tissue_NP source_NN information_NN for_IN approximately_RB 6900_CD human_JJ EST_NN libraries_NNS was_VBD exhaustively_RB examined_VBN to_TO produce_VB a_DT consistent_JJ classification_NN of_IN human_JJ tissues_NNS suitable_JJ for_IN tissue_NN specificity_NN calculations_NNS ._SENT We_PP checked_VBD and_CC refined_VBD the_DT NCBI_NP Library_NP Browser_NP classification_NN (_( 200_CD categories_NNS )_) to_TO produce_VB a_DT considerably_RB reduced_VBN classification_NN (_( 46_CD categories_NNS )_) ._SENT For_IN many_JJ libraries_NNS with_IN unclear_JJ or_CC incomplete_JJ tissue_NN information_NN in_IN UniGene_NP ,_, we_PP checked_VBD their_PP$ dbEST_JJ entries_NNS for_IN extra_JJ information_NN about_IN tissue_NN source_NN ._SENT Libraries_NNS recorded_VBN as_IN having_VBG the_DT same_JJ tissue_NN source_NN (_( e.g._FW '_POS brain_NN '_'' )_) were_VBD combined_VBN into_IN a_DT single_JJ category_NN ,_, including_VBG both_DT tumor_NN and_CC normal_JJ samples_NNS from_IN that_DT tissue_NN ._SENT We_PP sought_VBD to_TO avoid_VB mixing_VBG of_IN multiple_JJ tissues_NNS during_IN this_DT procedure_NN ._SENT If_IN a_DT library_NN could_MD not_RB be_VB clearly_RB assigned_VBN to_TO a_DT single_JJ tissue_NN (_( for_IN example_NN ,_, if_IN it_PP was_VBD a_DT pool_NN of_IN multiple_JJ samples_NNS from_IN different_JJ tissues_NNS ,_, or_CC lacked_VBD clear_JJ information_NN designating_VBG it_PP as_IN a_DT sample_NN from_IN a_DT single_JJ tissue_NN )_) ,_, it_PP was_VBD excluded_VBN from_IN the_DT final_JJ set_NN ._SENT We_PP excluded_VBD a_DT total_NN of_IN 2652_CD EST_JJ libraries_NNS by_IN these_DT criteria_NNS (_( see_VB Table_NP )_) ._SENT Our_PP$ final_JJ classification_NN consisted_VBN of_IN 4271_CD EST_JJ libraries_NNS in_IN just_RB 46_CD single_JJ tissue_NN categories_NNS (_( see_VB Table_NP )_) ._SENT Tissue_NN specificity_NN scoring_VBG |_SYM Reliable_JJ detection_NN of_IN tissue_NN specificity_NN is_VBZ complicated_VBN by_IN poor_JJ EST_JJ library_NN coverage_NN (_( in_IN many_JJ cases_NNS there_EX are_VBP few_JJ ESTs_NNS from_IN a_DT given_VBN tissue_NN for_IN a_DT given_VBN exon_NN )_) and_CC sampling_VBG bias_NN problems_NNS (_( different_JJ tissues_NNS may_MD have_VB dramatically_RB different_JJ numbers_NNS of_IN ESTs_JJ sequenced_NN )_) ._SENT We_PP therefore_RB needed_VBD a_DT statistical_JJ measure_NN of_IN tissue_NN specificity_NN that_WDT properly_RB accounts_VBZ for_IN these_DT sources_NNS of_IN uncertainty_NN and_CC bias_NN ._SENT Specifically_RB ,_, we_PP cannot_MD assume_VB that_IN the_DT observed_JJ numbers_NNS of_IN ESTs_NN from_IN one_CD tissue_NN exactly_RB reflect_VBP the_DT true_JJ proportions_NNS of_IN different_JJ splice_NN forms_NNS in_IN that_DT tissue_NN ._SENT A_DT larger_JJR number_NN of_IN ESTs_NP gives_VBZ a_DT more_RBR confident_JJ estimate_NN of_IN those_DT proportions_NNS ;_: a_DT smaller_JJR number_NN of_IN ESTs_JJ causes_NNS increased_VBD uncertainty_NN ._SENT To_TO take_VB this_DT into_IN account_NN rigorously_RB when_WRB attempting_VBG to_TO compare_VB the_DT proportions_NNS of_IN a_DT given_VBN splice_NN form_NN between_IN different_JJ tissues_NNS we_PP used_VBD Bayesian_NP statistics_NNS ,_, treating_VBG the_DT true_JJ proportions_NNS as_IN hidden_JJ variables_NNS and_CC calculating_VBG confidence_NN from_IN the_DT available_JJ observations_NNS ._SENT Suppose_VB gene_NN G_NN has_VBZ two_CD mutually_RB exclusive_JJ (_( i.e._FW alternative_NN )_) splices_VBZ S1_NP and_CC S2_NP ._SENT By_IN '_'' mutually_RB exclusive_JJ '_'' we_PP mean_VBP two_CD splices_NNS that_DT share_NN one_CD splice_NN site_NN but_CC differ_VB at_IN the_DT other_JJ splice_NN site_NN and_CC which_WDT thus_RB cannot_MD both_CC be_VB present_JJ in_IN a_DT single_JJ transcript_NN ._SENT Throughout_IN this_DT paper_NN we_PP will_MD refer_VB to_TO the_DT set_NN of_IN transcripts_NNS containing_VBG splice_NN S1_NN as_RB '_POS splice_NN form_NN S1_NP '_POS ._SENT For_IN our_PP$ hidden_JJ variables_NNS ,_, let_VB theta1T_NN represent_VB the_DT hidden_JJ frequency_NN of_IN S1_NP in_IN a_DT specific_JJ tissue_NN T_NN and_CC let_VBP theta1similar_NN be_VB its_PP$ frequency_NN in_IN the_DT pool_NN of_IN all_DT other_JJ tissues_NNS (_( i.e._FW all_DT tissues_NNS except_IN T_NN ,_, symbolized_VBN by_IN similar_JJ )_) ._SENT Similarly_RB ,_, let_VB theta2T_NN and_CC theta2similar_NN represent_VBP the_DT hidden_JJ frequencies_NNS of_IN S2_NP in_IN tissue_NN T_NN versus_CC in_IN the_DT pool_NN of_IN all_DT other_JJ tissues_NNS similar_JJ ._SENT By_IN definition_NN ,_, these_DT probabilities_NNS must_MD be_VB normalized_VBN :_: theta1T_NN +_SYM theta2T_NP =_SYM 1_CD theta1similar_NN +_SYM theta2similar_NN =_SYM 1_CD For_IN our_PP$ observations_NNS ,_, let_VBD N1T_NP and_CC N2T_NP be_VB the_DT total_JJ number_NN of_IN ESTs_NN in_IN tissue_NN T_NN observed_VBD to_TO have_VB splice_NN S1_NP or_CC S2_NP ,_, respectively_RB ._SENT Similarly_RB ,_, let_VB N1similar_NN and_CC N2similar_NN be_VB the_DT total_JJ number_NN of_IN ESTs_NN in_IN the_DT pool_NN of_IN all_DT other_JJ tissues_NNS similar_JJ observed_VBD to_TO have_VB splice_NN S1_NP or_CC S2_NP ,_, respectively_RB ._SENT Since_IN our_PP$ model_NN assumes_VBZ two_CD mutually_RB exclusive_JJ splice_NN forms_NNS ,_, the_DT likelihood_NN of_IN the_DT observations_NNS should_MD follow_VB a_DT simple_JJ binomial_JJ distribution_NN ._SENT For_IN example_NN ,_, in_IN tissue_NN T_NN We_PP first_RB calculated_VBD the_DT confidence_NN that_IN splice_NN S1_NP is_VBZ preferred_JJ in_IN tissue_NN T_NN as_IN a_DT Bayesian_NP posterior_JJ probability_NN :_: We_PP used_VBD P(theta1T)_NP =_SYM 1_CD as_IN an_DT uninformative_JJ prior_JJ probability_NN ._SENT We_PP also_RB computed_VBD the_DT posterior_JJ probability_NN that_WDT splice_VBP S1_NP is_VBZ preferred_JJ in_IN the_DT pool_NN of_IN all_DT other_JJ tissues[P(theta1similar_NN >_SYM 50%|obs_VBZ )_) ]_SYM in_IN the_DT same_JJ way_NN ,_, from_IN the_DT counts_NNS N1similar_NP and_CC N2similar_NP ._SENT We_PP defined_VBD a_DT tissue_NN specificity_NN (_( TS_NP )_) score_NN of_IN splice_NN S1_NN for_IN tissue_NN T_NN as_IN the_DT difference_NN between_IN this_DT posterior_JJ probability_NN for_IN tissue_NN T_NN versus_IN the_DT pool_NN of_IN other_JJ tissues_NNS ,_, TS_NP =_SYM 100[P(theta1T_NP >_SYM 50%|obs_NP )_) --_: P(theta1similar_NP >_SYM 50%|obs_VBZ )_) ]_SYM To_TO assess_VB how_WRB stable_JJ the_DT TS_NP value_NN is_VBZ to_TO possible_JJ error_NN models_NNS ,_, we_PP calculated_VBD a_DT robustness_NN value_NN rTS_NNS ,_, which_WDT measures_VBZ how_WRB much_JJ the_DT TS_NP value_NN drops_VBZ when_WRB a_DT single_JJ EST_NN observation_NN of_IN splice_NN S1_NP is_VBZ removed_VBN from_IN tissue_NN T._NP Specifically_RB ,_, we_PP computed_VBD the_DT negative_JJ log_NN value_NN of_IN the_DT relative_JJ change_NN of_IN the_DT TS_NP value_NN caused_VBN by_IN removing_VBG that_DT EST_NN ,_, rTS_NNS =_SYM --_: log10(DeltaTS_NNS /TS_NNS )_) ,_, where_WRB DeltaTS_NP =_SYM |TS(N1T)_NN --_: TS(N1T_NP --_: 1)|_JJ ._SENT rTS_NN =_SYM 1_CD means_NNS TS_NP drops_VBZ by_IN 10_CD --_: 1_CD =_SYM 10_CD %_NN and_CC rTS_NNS =_SYM 0_CD means_NNS TS_NP drops_VBZ to_TO 0_CD ._SENT Because_IN each_DT EST_NN makes_VBZ an_DT equal_JJ contribution_NN to_TO the_DT TS_NP value_NN ,_, only_RB one_CD resampling_NN step_NN was_VBD required_VBN to_TO calculate_VB rTS_NNS ._SENT We_PP also_RB calculated_JJ rTSsimilar_NN ,_, the_DT effect_NN of_IN removing_VBG one_CD EST_NN observation_NN of_IN splice_NN S2_NN from_IN the_DT pool_NN of_IN other_JJ tissues_NNS ,_, defined_VBN in_IN the_DT same_JJ way_NN as_IN rTS_NNS ,_, using_VBG DeltaTS_NNS =_SYM |TS(N2similar)_NN --_: TS(N2similar_NP --_: 1)|_JJ ._SENT Criteria_NNS for_IN high_JJ confidence_NN (_( HC_NP )_) tissue_NN specificity_NN were_VBD TS_NP >_SYM 50_CD ,_, rTS_NNS >_SYM 0.9_CD ,_, rTSsimilar_NN >_SYM 0.9_CD ;_: for_IN low_JJ confidence_NN (_( LC_NP )_) TS_NP >_SYM 0_CD ,_, rTS_NNS >_SYM 0.5_CD ,_, rTSsimilar_NN >_SYM 0.5_CD ._SENT A_DT necessary_JJ (_( but_CC insufficient_JJ )_) condition_NN for_IN the_DT HC_NP group_NN was_VBD at_IN least_JJS three_CD EST_JJ observations_NNS of_IN S1_NP in_IN tissue_NN T_NN ;_: for_IN LC_NP at_IN least_JJS two_CD EST_JJ observations_NNS of_IN S1_NP in_IN tissue_NN T._NP Validation_NP of_IN tissue-specific_JJ splices_NNS of_IN known_JJ genes_NNS |_SYM To_TO search_VB for_IN alternative_JJ splicing_VBG information_NN for_IN a_DT given_VBN gene_NN ,_, we_PP performed_VBD thorough_JJ literature_NN searches_NNS using_VBG PubMed_NP ,_, OMIM_NP ,_, LocusLink_NP and_CC other_JJ databases_NNS of_IN alternative_NN splicing_VBG ._SENT We_PP sought_VBD information_NN about_IN sequencing_VBG of_IN alternative_JJ splice_NN forms_NNS and_CC their_PP$ tissue_NN specificity_NN ._SENT Isoform_NN data_NNS without_IN a_DT complete_JJ reported_JJ sequence_NN was_VBD not_RB considered_VBN sufficient_JJ validation_NN ._SENT To_TO be_VB counted_VBN as_IN a_DT match_NN ,_, an_DT alternative_JJ splice_NN identified_VBN in_IN our_PP$ database_NN had_VBD to_TO match_VB a_DT specific_JJ transcript_NN sequence_NN published_VBN in_IN the_DT literature_NN ._SENT To_TO be_VB counted_VBN as_IN a_DT validated_VBN tissue_NN specificity_NN the_DT isoform_NN also_RB had_VBD to_TO be_VB independently_RB reported_VBN to_TO be_VB specific_JJ to_TO the_DT same_JJ tissue_NN that_IN we_PP identified_VBD ._SENT For_IN the_DT validation_NN data_NNS shown_VBN in_IN Table_NP we_PP validated_VBD a_DT sample_NN set_VBD consisting_VBG of_IN all_DT brain-specific_JJ and_CC muscle-specific_JJ alternative_JJ splices_NNS identified_VBN by_IN our_PP$ HC_NP criteria_NNS on_IN a_DT previous_JJ dataset_NN (_( UniGene_NP and_CC human_JJ genomic_JJ sequence_NN data_NNS February_NP 2001_CD )_) ._SENT All_DT procedures_NNS and_CC criteria_NNS were_VBD identical_JJ for_IN different_JJ runs_NNS ._SENT We_PP also_RB used_VBD the_DT GeneMine_NP software_NN system_NN to_TO visualize_VB and_CC validate_VB versus_IN the_DT literature_NN all_DT aspects_NNS of_IN the_DT genomic_JJ mapping_NN of_IN our_PP$ clusters_NNS ,_, exons_NNS and_CC introns_NNS ,_, splices_NNS sites_NNS ,_, alternative_JJ splicing_VBG and_CC the_DT impacts_NNS on_IN protein_NN structure_NN and_CC function_NN ,_, by_IN examining_VBG all_PDT the_DT features_NNS in_IN the_DT genomic_JJ --_: EST_NN --_: mRNA_NN multiple_JJ sequence_NN alignments_NNS ._SENT Bioinformatics_NP analysis_NN of_IN tissue-specific_JJ protein_NN isoforms_NNS |_SYM To_TO assess_VB the_DT effects_NNS of_IN alternative_NN splicing_VBG on_IN the_DT protein_NN product_NN ,_, we_PP predicted_VBD protein_NN isoform_NN sequences_NNS for_IN each_DT alternative_JJ splice_NN ,_, their_PP$ protein_NN domain_NN composition_NN and_CC motif_NN analysis_NN ._SENT These_DT results_NNS will_MD be_VB described_VBN in_IN detail_NN elsewhere_RB ._SENT ORF_NP prediction_NN was_VBD performed_VBN using_VBG standard_JJ methods_NNS for_IN identifying_VBG the_DT longest_JJS open_JJ reading_NN frame_NN in_IN each_DT transcript_NN ._SENT Protein_NN domain_NN prediction_NN was_VBD performed_VBN using_VBG RPS-BLAST_NN on_IN the_DT protein_NN isoform_NN sequences_NNS ,_, against_IN a_DT database_NN of_IN protein_NN domain_NN sequences_NNS from_IN SMART_NP and_CC PFAM_NP ,_, using_VBG cut-off_NN thresholds_NNS of_IN 10_CD --_: 20_CD expectation_NN ._SENT For_IN all_PDT the_DT examples_NNS with_IN functional_JJ importance_NN shown_VBN in_IN this_DT paper_NN we_PP also_RB evaluated_VBD the_DT effects_NNS of_IN each_DT alternative_JJ splice_NN relationship_NN by_IN carefully_RB examining_VBG the_DT complete_JJ alignment_NN of_IN ESTs_NN to_TO genomic_JJ sequence_NN using_VBG GeneMine_NP software_NN ._SENT Since_IN an_DT alternative_JJ splice_NN can_MD change_VB where_WRB the_DT coding_VBG region_NN starts_VBZ and_CC ends_VBZ ,_, we_PP adopted_VBD the_DT policy_NN that_IN any_DT alternative_JJ splice_NN that_WDT alters_VBZ the_DT protein_NN product_NN will_MD be_VB classified_VBN as_IN a_DT '_'' coding_VBG region_NN '_POS ,_, regardless_RB of_IN its_PP$ location_NN relative_JJ to_TO the_DT GenBank_NP CDS_NP annotation_NN ._SENT Table_NP 1_CD |_SYM Construction_NN of_IN our_PP$ EST_JJ library_NN tissue_NN classification_NN Table_NP 2_CD |_SYM Our_JJ EST_JJ library_NN classification_NN database_NN of_IN 46_CD human_JJ tissues_NNS Table_NP 6_CD |_SYM Validation_NN of_IN brain-_NN and_CC muscle-specific_JJ isoforms_NNS versus_CC independent_JJ literature_NN Tissue_NP classification_NN of_IN human_JJ ESTs_NNS |_SYM Since_IN the_DT cDNA_NN library_NN source_NN of_IN each_DT public_JJ EST_NN sequence_NN is_VBZ recorded_VBN ,_, in_IN principle_NN this_DT dataset_NN could_MD provide_VB large-scale_JJ detection_NN of_IN tissue-specific_JJ alternative_NN splicing_VBG ,_, if_IN each_DT cDNA_NN library_NN could_MD be_VB associated_VBN with_IN a_DT specific_JJ tissue_NN ._SENT Unfortunately_RB ,_, these_DT data_NNS are_VBP from_IN many_JJ different_JJ contributors_NNS and_CC are_VBP not_RB annotated_VBN in_IN a_DT uniform_JJ way_NN ._SENT To_TO provide_VB a_DT reliable_JJ basis_NN for_IN analyzing_VBG tissue_NN specificity_NN ,_, we_PP have_VBP carefully_RB classified_VBN the_DT approximately_RB 7000_CD human_JJ EST_JJ libraries_NNS into_IN distinct_JJ tissue_NN classes_NNS ._SENT We_PP began_VBD with_IN the_DT NCBI_NP Library_NP Browser_NP classification_NN ,_, which_WDT consists_VBZ of_IN 200_CD categories_NNS covering_VBG 6923_CD libraries_NNS ._SENT Manually_RB inspecting_VBG public_JJ information_NN about_IN cDNA_NN libraries_NNS available_JJ from_IN Unigene_NP ,_, dbEST_NP and_CC GenBank_NP ,_, we_PP combined_VBD different_JJ categories_NNS that_WDT were_VBD from_IN the_DT same_JJ tissue_NN ,_, excluded_VBN many_JJ categories_NNS (_( e.g._FW '_POS head_NN and_CC neck_NN '_'' )_) that_WDT did_VBD not_RB correspond_VB to_TO a_DT specific_JJ tissue_NN and_CC constructed_VBN a_DT manually_RB curated_VBD library_NN tissue_NN classification_NN database_NN ._SENT For_IN this_DT study_NN we_PP combined_VBD tumor_NN and_CC normal_JJ samples_NNS from_IN each_DT tissue_NN source_NN (_( e.g._FW '_POS brain_NN '_'' )_) ,_, although_IN in_IN the_DT future_NN it_PP will_MD be_VB interesting_JJ to_TO look_VB for_IN tissue_NN specificities_NNS that_WDT distinguish_VBP these_DT ._SENT Our_PP$ final_JJ classification_NN consisted_VBN of_IN 46_CD tissues_NNS containing_VBG 4271_CD cDNA_NN libraries_NNS and_CC 2.2_CD million_CD human_JJ ESTs_NNS ._SENT This_DT represents_VBZ 75_CD %_NN of_IN ESTs_NN in_IN UniGene_NP ._SENT This_DT classification_NN is_VBZ by_IN no_DT means_VBZ an_DT optimally_RB structured_VBN subdivision_NN of_IN the_DT distinct_JJ tissues_NNS in_IN the_DT human_JJ body_NN ,_, but_CC rather_RB is_VBZ intended_VBN to_TO reflect_VB the_DT level_NN of_IN specificity_NN present_NN in_IN the_DT public_JJ cDNA_NN library_NN samples_VBZ themselves_PP ._SENT These_DT samples_NNS are_VBP rarely_RB more_RBR specific_JJ than_IN an_DT entire_JJ organ_NN (_( e.g._FW '_POS brain_NN '_'' )_) ._SENT As_IN an_DT example_NN of_IN our_PP$ tissue_NN classification_NN ,_, Table_NP lists_VBZ all_PDT the_DT libraries_NNS classified_VBN as_RB '_'' adipose_NN '_POS tissue_NN ._SENT Genome-wide_JJ detection_NN of_IN alternative_JJ splicing_VBG |_SYM Using_VBG the_DT latest_JJS human_JJ EST_JJ data_NNS (_( UniGene_NP January_NP 2002_CD )_) and_CC genomic_JJ sequence_NN we_PP performed_VBD a_DT genome-wide_JJ analysis_NN of_IN alternative_NN splicing_VBG as_IN previously_RB described_VBN ._SENT This_DT conservative_JJ analysis_NN process_NN takes_VBZ into_IN account_NN many_JJ factors_NNS ,_, including_VBG mapping_NN of_IN EST_JJ consensus_NN sequences_NNS to_TO unique_JJ genomic_JJ locations_NNS ,_, validation_NN by_IN intronic_JJ splice_NN site_NN sequences_NNS and_CC very_RB specific_JJ match_NN requirements_NNS (_( two_CD mutually_RB exclusive_JJ splices_NNS that_WDT match_VBP exactly_RB at_IN one_CD splice_NN site_NN but_CC diverge_VB at_IN the_DT other_JJ splice_NN site_NN )_) to_TO report_VB an_DT alternative_JJ splice_NN ._SENT This_DT analysis_NN identified_VBD 27_CD 790_CD alternative_JJ splices_NNS (_( see_VB Table_NP )_) ,_, approximately_RB four_CD times_NNS that_DT of_IN our_PP$ previous_JJ analysis_NN ._SENT These_DT results_NNS will_MD be_VB accessible_JJ via_IN our_PP$ online_JJ Human_NP Alternative_NP Splicing_NP Database_NP ._SENT Detection_NN of_IN tissue-specific_JJ alternative_NN splicing_VBG |_SYM To_TO identify_VB tissue-specific_JJ alternative_NN splicing_VBG automatically_RB and_CC with_IN statistical_JJ robustness_NN ,_, we_PP developed_VBD a_DT tissue_NN specificity_NN (_( TS_NP )_) scoring_VBG function_NN ._SENT This_DT calculation_NN measures_VBZ the_DT percent_NN confidence_NN that_IN a_DT specific_JJ splice_NN S1_NP is_VBZ preferred_JJ in_IN a_DT given_VBN tissue_NN T1_NN (_( i.e._FW that_IN S1_NP is_VBZ found_VBN in_IN a_DT larger_JJR proportion_NN of_IN transcripts_NNS there_RB than_IN the_DT alternative_JJ splice_NN S2_NP )_) ,_, minus_CC the_DT same_JJ confidence_NN calculated_VBN for_IN the_DT pool_NN of_IN ESTs_NN from_IN all_DT other_JJ tissues_NNS (_( see_VB Materials_NNS and_CC Methods_NNS for_IN details_NNS )_) ._SENT TS_NP >_SYM 0_CD means_NNS that_WDT splice_VBP S1_NP is_VBZ preferred_JJ in_IN tissue_NN T1_NN more_JJR than_IN it_PP is_VBZ in_IN other_JJ tissues_NNS ._SENT The_DT higher_JJR the_DT TS_NP score_NN is_VBZ ,_, the_DT stronger_JJR the_DT evidence_NN of_IN tissue_NN specificity_NN ._SENT For_IN example_NN ,_, if_IN the_DT confidence_NN that_IN splice_NN S1_NP is_VBZ the_DT major_JJ splice_NN form_NN was_VBD 70_CD %_NN in_IN brain_NN and_CC 40_CD %_NN in_IN the_DT pool_NN of_IN other_JJ tissues_NNS ,_, then_RB the_DT TS_NP score_NN would_MD be_VB 70_CD --_: 40_CD =_SYM 30_CD ._SENT If_IN splice_NN S1_NP is_VBZ preferred_JJ in_IN all_DT tissues_NNS ,_, it_PP will_MD get_VB a_DT low_JJ TS_NP score_NN ._SENT If_IN there_EX are_VBP insufficient_JJ EST_NN counts_VBZ to_TO be_VB confident_JJ about_IN the_DT proportion_NN of_IN S1_NP in_IN tissue_NN T1_JJ or_CC other_JJ tissues_NNS ,_, this_DT will_MD also_RB give_VB a_DT low_JJ TS_NP score_NN ,_, both_CC by_IN decreasing_VBG the_DT certainty_NN that_IN splice_NN S1_NP is_VBZ preferred_JJ in_IN tissue_NN T1_NN and_CC increasing_VBG the_DT possibility_NN that_WDT splice_VBP S1_NP might_MD be_VB preferred_JJ in_IN other_JJ tissues_NNS as_IN well_RB ._SENT Table_NN illustrates_VBZ the_DT use_NN of_IN the_DT TS_NP score_NN to_TO distinguish_VB tissue-specific_JJ splicing_VBG within_IN ESTs_NN from_IN one_CD gene_NN (_( GAR22_NP ,_, UniGene_NP cluster_NN Hs.322852_NP )_) ._SENT We_PP identified_VBD two_CD alternative_NN splicing_VBG relationships_NNS in_IN this_DT cluster_NN (_( indicated_VBN in_IN Table_NP by_IN their_PP$ splice_NN IDs_NNS ,_, 17571_CD --_: 17572_CD and_CC 17577_CD --_: 17578_LS )_) and_CC calculated_JJ TS_NP scores_NNS for_IN these_DT alternative_JJ splices_NNS in_IN the_DT tissues_NNS in_IN which_WDT they_PP were_VBD observed_VBN ._SENT Of_IN 11_CD candidate_NN splice_NN --_: tissue_NN pairs_NNS ,_, four_CD had_VBD a_DT positive_JJ TS_NP score_NN ._SENT However_RB ,_, the_DT number_NN of_IN EST_JJ observations_NNS supporting_VBG these_DT scores_NNS was_VBD not_RB large_JJ ._SENT To_TO take_VB this_DT into_IN account_NN ,_, we_PP calculated_VBD the_NP '_POS robustness_NN '_'' of_IN the_DT TS_NP score_NN ,_, which_WDT measures_VBZ how_WRB much_JJ TS_NP drops_NNS when_WRB a_DT single_JJ EST_NN observation_NN of_IN splice_NN S1_NN in_IN tissue_NN T1_NP is_VBZ removed_VBN from_IN the_DT sample_NN ._SENT This_DT assesses_VBZ how_WRB stable_JJ the_DT TS_NP value_NN is_VBZ to_TO possible_JJ error_NN models_NNS (_( e.g._FW the_DT library_NN classification_NN may_MD have_VB errors_NNS )_) and_CC is_VBZ analogous_JJ to_TO the_DT '_'' jack-knife_NN '_POS ,_, a_DT common_JJ statistical_JJ resampling_NN method_NN ._SENT Defining_VBG the_DT robustness_NN as_IN rTS_NNS =_SYM --_: log10(DeltaTS_NNS /TS_NNS )_) ,_, where_WRB DeltaTS_NP =_SYM |TS(N1T)_NN --_: TS(N1T_NP --_: 1)|_NP (_( see_VB Materials_NNS and_CC Methods_NNS for_IN details_NNS )_) ,_, rTS_NN =_SYM 1_CD means_NNS TS_NP drops_VBZ by_IN 10_CD --_: 1_CD =_SYM 10_CD %_NN and_CC rTS_NNS =_SYM 0_CD means_NNS TS_NP drops_VBZ to_TO 0_CD ._SENT This_DT measures_VBZ the_DT amount_NN of_IN EST_JJ evidence_NN supporting_VBG the_DT TS_NP score_NN ;_: if_IN N1T_NP >>_NP 1_CD ,_, then_RB the_DT robustness_NN ,_, rTS_NNS ,_, can_MD be_VB high_JJ ._SENT Only_RB one_CD candidate_NN tissue-specific_JJ splice_NN in_IN GAR22_NP (_( splice_NN ID_NP 17571_CD in_IN tissue_NN eye_retina_NN )_) passes_VBZ the_DT combined_JJ criteria_NNS of_IN >2-fold_NN tissue_NN specificity_NN (_( TS_NP >_SYM 50_CD )_) and_CC good_JJ robustness_NN (_( rTS_NNS >_SYM 0.9_CD ,_, equivalent_JJ to_TO a_DT 14_CD point_NN drop_NN in_IN TS_NP ;_: see_VBP Materials_NNS and_CC Methods_NNS for_IN details_NNS )_) ._SENT It_PP is_VBZ striking_JJ that_IN the_DT only_JJ other_JJ observations_NNS of_IN this_DT splice_NN form_NN are_VBP in_IN brain_NN ,_, which_WDT suggests_VBZ that_IN the_DT putative_JJ association_NN of_IN this_DT form_NN with_IN eye_retina_NN is_VBZ real_JJ and_CC that_IN this_DT form_NN may_MD be_VB found_VBN exclusively_RB in_IN neuronal_JJ tissue_NN ._SENT We_PP have_VBP computed_VBN TS_NP scores_NNS for_IN all_DT alternative_JJ splices_NNS detected_VBN in_IN the_DT EST_JJ libraries_NNS contained_VBN in_IN our_PP$ 46_CD tissue_NN classification_NN database_NN ._SENT We_PP divided_VBD those_DT with_IN positive_JJ TS_NP scores_NNS into_IN two_CD groups_NNS :_: a_DT HC_NP group_NN with_IN TS_NP >_SYM 50_CD %_NN and_CC rTS_NNS >_SYM 0.9_CD ,_, designed_VBN to_TO screen_VB out_RP false_JJ positives_NNS (_( but_CC causing_VBG a_DT high_JJ level_NN of_IN false_JJ negatives_NNS )_) ,_, and_CC a_DT LC_NP group_NN with_IN TS_NP >_SYM 0_CD and_CC rTS_NNS >_SYM 0.5_CD ._SENT We_PP identified_VBD 894_CD tissue-specific_JJ relationships_NNS for_IN 667_CD alternative_JJ splices_NNS in_IN the_DT HC_NP group_NN and_CC a_DT total_NN of_IN 2873_CD alternative_JJ splices_NNS showing_VBG tissue_NN specificity_NN in_IN the_DT LC_NP group_NN ._SENT These_DT data_NNS suggest_VBP that_IN by_IN our_PP$ HC_NP criteria_NNS 10.4_CD %_NN of_IN alternatively_RB spliced_VBN genes_NNS in_IN the_DT human_JJ genome_NN have_VBP tissue_NN specificity_NN discernible_JJ in_IN current_JJ EST_JJ data_NNS ,_, and_CC 30.6_CD %_NN by_IN our_PP$ LC_NP criteria_NNS ._SENT Given_VBN the_DT very_RB gross_JJ form_NN of_IN tissue_NN specificity_NN of_IN the_DT EST_JJ libraries_NNS (_( typically_RB an_DT entire_JJ organ_NN rather_RB than_IN a_DT specific_JJ cell_NN type_NN )_) ,_, this_DT probably_RB underestimates_VBZ the_DT true_JJ extent_NN of_IN tissue-specific_JJ alternative_NN splicing_VBG ._SENT Independent_JJ validation_NN of_IN our_PP$ tissue_NN specificity_NN results_NNS |_SYM We_PP have_VBP performed_VBN extensive_JJ validation_NN analysis_NN of_IN our_PP$ tissue-specific_JJ alternative_JJ splice_NN forms_NNS ._SENT Figure_NN shows_VBZ one_CD example_NN of_IN brain-specific_JJ alternative_NN splicing_VBG detected_VBN automatically_RB by_IN our_PP$ procedure_NN in_IN the_DT IRF3_NP gene_NN (_( Hs.75254_NP ,_, interferon_NN regulatory_JJ factor-3_NN )_) with_IN a_DT TS_NP score_NN of_IN 88_CD ._SENT IRF3_NP is_VBZ a_DT member_NN of_IN the_DT IRF_NP family_NN and_CC plays_VBZ an_DT important_JJ role_NN in_IN the_DT virus-_NN and_CC double-stranded_JJ RNA-mediated_JJ induction_NN of_IN interferon_NN beta_NN (_( IFNbeta_NP )_) and_CC RANTES_NP (_( regulated_VBN upon_IN activation_NN normal_JJ T_NN cell_NN expressed_VBN and_CC secreted_VBN )_) (_( ,_, )_) ._SENT Our_PP$ automated_JJ procedure_NN detected_VBD two_CD alternative_NN splice_NN forms_NNS :_: a_DT longer_JJR mRNA_NN consisting_VBG of_IN eight_CD exons_NNS and_CC a_DT short_JJ form_NN in_IN which_WDT exons_NNS I_PP and_CC II_NP are_VBP replaced_VBN by_IN a_DT new_JJ exon_NN IIa_NNS ._SENT These_DT match_NN isoforms_NNS reported_VBD in_IN the_DT literature_NN as_IN IRF3_NP and_CC IRF3a_NP ._SENT In_IN the_DT EST_JJ data_NNS we_PP detected_VBD five_CD ESTs_NN in_IN brain_NN ,_, all_RB matching_VBG the_DT IRF3a_NP form_NN ,_, and_CC five_CD ESTs_NNS elsewhere_RB ,_, of_IN which_WDT four_CD match_NN the_DT IRF3_NP form_NN ._SENT According_VBG to_TO the_DT literature_NN ,_, both_DT isoforms_NNS are_VBP expressed_VBN in_IN multiple_JJ tissues_NNS but_CC the_DT ratio_NN IRF3a:IRF3_NN is_VBZ dramatically_RB high_JJ in_IN brain_NN compared_VBN with_IN other_JJ human_JJ tissues_NNS ._SENT This_DT example_NN also_RB illustrates_VBZ the_DT functional_JJ interpretability_NN of_IN the_DT large_JJ structural_JJ changes_NNS that_IN alternative_NN splicing_VBG often_RB causes_VBZ ._SENT We_PP performed_VBD a_DT series_NN of_IN bioinformatics_NN analyses_NNS to_TO predict_VB the_DT protein_NN isoform_NN sequences_NNS and_CC protein_NN structural_JJ domains_NNS (_( see_VB Materials_NNS and_CC Methods_NNS )_) ._SENT Prediction_NN of_IN the_DT protein_NN products_NNS identified_VBD an_DT ORF_NP in_IN both_DT cases_NNS ,_, revealing_VBG a_DT replacement_NN AUG_NP start_NN site_NN in_IN exon_NN IIa_NNS that_WDT encodes_VBZ 22_CD amino_NN acids_NNS before_IN entering_VBG exon_NN III_NP in_IN the_DT same_JJ coding_VBG frame_NN as_IN in_IN the_DT long_JJ IRF3_NP form_NN ._SENT Protein_NN domain_NN prediction_NN using_VBG SMART_NP and_CC PFAM_NP showed_VBD that_IN the_DT brain-specific_JJ splice_NN disrupts_VBZ the_DT 110_CD amino_NN acid_JJ DNA-binding_NP domain_NN (_( PFAM_NP id_NN 00605_CD )_) at_IN the_DT IRF3_NP N-terminus_NP ,_, by_IN replacing_VBG the_DT first_JJ 55_CD amino_NN acids_NNS with_IN the_DT 22_CD amino_NN acids_NNS from_IN exon_NN IIa_NNS (_( Fig._NN B_NN )_) ._SENT On_IN the_DT basis_NN of_IN this_DT simple_JJ domain_NN analysis_NN ,_, we_PP would_MD predict_VB that_IN in_IN brain_NN the_DT role_NN of_IN IRF3_NP in_IN regulating_VBG gene_NN expression_NN (_( e.g._FW activating_VBG IFNbeta_NP and_CC RANTES_NP )_) would_MD be_VB dramatically_RB altered_VBN ._SENT This_DT is_VBZ strongly_RB validated_VBN by_IN the_DT published_VBN literature_NN ._SENT IRF3_NP has_VBZ been_VBN shown_VBN to_TO bind_VB to_TO the_DT IFNbeta_NP promoter_NN and_CC up-regulate_VB the_DT transcription_NN of_IN IFNbeta_NP with_IN other_JJ enhancers_NNS after_IN virus_NN infection_NN (_( ,_, )_) ._SENT The_DT brain-specific_JJ splice_NN eliminates_VBZ the_DT ability_NN of_IN IRF3_NP to_TO bind_VB to_TO the_DT IFNbeta_NP promoter_NN in_IN vitro_NN and_CC seems_VBZ to_TO play_VB a_DT protective_JJ role_NN in_IN brain_NN ,_, reducing_VBG the_DT toxic_JJ effect_NN of_IN IFNbeta_NP (_( ,_, )_) by_IN suppressing_VBG its_PP$ expression_NN in_IN brain_NN ._SENT To_TO assess_VB the_DT overall_JJ accuracy_NN of_IN our_PP$ automated_JJ tissue_NN specificity_NN detection_NN method_NN for_IN many_JJ genes_NNS ,_, we_PP followed_VBD this_DT same_JJ procedure_NN of_IN testing_NN for_IN independent_JJ validation_NN of_IN our_PP$ results_NNS ._SENT We_PP used_VBD two_CD tissues_NNS ,_, brain_NN and_CC muscle_NN ,_, as_IN the_DT test_NN samples_NNS for_IN this_DT validation_NN ,_, since_IN many_JJ studies_NNS of_IN alternative_JJ splicing_VBG have_VB been_VBN done_VBN for_IN genes_NNS in_IN these_DT tissues_NNS ._SENT For_IN a_DT random_JJ sample_NN of_IN 37_CD tissue-specific_JJ alternative_NN splices_NNS identified_VBN in_IN the_DT HC_NP group_NN for_IN these_DT tissues_NNS ,_, we_PP searched_VBD the_DT published_VBN literature_NN to_TO see_VB whether_IN tissue_NN specificity_NN was_VBD independently_RB reported_VBN for_IN those_DT genes_NNS ._SENT To_TO count_VB a_DT splice_NN form_NN as_IN validated_VBN ,_, we_PP required_VBD that_IN a_DT complete_JJ sequence_NN matching_VBG our_PP$ splice_NN form_NN be_VB found_VBN in_IN the_DT literature_NN and_CC be_VB demonstrated_VBN to_TO be_VB specific_JJ to_TO the_DT tissue_NN reported_VBD by_IN our_PP$ procedure_NN ._SENT Previously_RB unknown_JJ genes_NNS (_( e.g._FW Hs.7973_NP )_) were_VBD excluded_VBN from_IN this_DT analysis_NN ,_, since_IN no_DT studies_NNS of_IN their_PP$ tissue-specific_JJ alternative_NN splicing_VBG have_VB been_VBN published_VBN ._SENT We_PP found_VBD that_IN 80_CD %_NN (_( 8_CD /10_CD )_) of_IN our_PP$ brain-_NN and_CC muscle-specific_JJ splices_NNS were_VBD validated_VBN by_IN the_DT existing_JJ literature_NN ._SENT In_IN the_DT two_CD cases_NNS where_WRB the_DT splice_NN forms_NNS were_VBD not_RB validated_VBN by_IN a_DT matching_VBG isoform_NN in_IN the_DT literature_NN ,_, published_VBN papers_NNS reported_VBD a_DT different_JJ isoform_NN that_WDT matched_VBD our_PP$ tissue_NN specificity_NN ._SENT For_IN example_NN ,_, in_IN Hs.57435_NP we_PP detected_VBD a_DT brain-specific_JJ alternative_NN splice_NN ._SENT This_DT splice_NN was_VBD not_RB validated_VBN by_IN a_DT matching_VBG sequence_NN in_IN the_DT literature_NN ,_, but_CC another_DT isoform_NN was_VBD reported_VBN and_CC shown_VBN to_TO be_VB brain-specific_JJ ._SENT Unfortunately_RB ,_, there_EX are_VBP no_DT ESTs_NN from_IN brain_NN that_WDT align_VBP to_TO this_DT region_NN of_IN the_DT gene_NN ,_, so_IN there_EX was_VBD no_DT possibility_NN of_IN our_PP$ detecting_VBG this_DT form_NN ._SENT Similarly_RB ,_, our_PP$ muscle-specific_JJ alternative_JJ splice_NN for_IN Hs.239069_NP was_VBD not_RB validated_VBN by_IN the_DT literature_NN ,_, but_CC another_DT isoform_NN of_IN this_DT gene_NN was_VBD reported_VBN to_TO be_VB muscle-specific_JJ ._SENT These_DT coincidences_NNS suggest_VBP that_IN even_RB the_DT tissue_NN specificities_NNS we_PP detected_VBD for_IN these_DT genes_NNS may_MD not_RB actually_RB be_VB incorrect_JJ ._SENT There_EX were_VBD five_CD additional_JJ cases_NNS where_WRB the_DT splice_NN form_NN we_PP detected_VBD was_VBD validated_VBN by_IN the_DT literature_NN but_CC no_DT tissue_NN specificity_NN studies_NNS were_VBD reported_VBN ._SENT Within_IN the_DT limits_NNS of_IN available_JJ published_VBN data_NNS ,_, these_DT results_NNS indicate_VBP that_IN the_DT reliability_NN of_IN our_PP$ database_NN is_VBZ likely_JJ to_TO be_VB high_JJ ._SENT We_PP have_VBP also_RB used_VBN these_DT data_NNS to_TO estimate_VB the_DT fraction_NN of_IN our_PP$ results_NNS that_WDT are_VBP novel_JJ discoveries_NNS of_IN tissue-specific_JJ alternative_NN splicing_VBG ._SENT These_DT come_VBP from_IN two_CD categories_NNS :_: detecting_VBG previously_RB unknown_JJ tissue_NN specificity_NN for_IN a_DT known_VBN alternative_NN splice_NN (_( in_IN a_DT known_VBN gene_NN )_) ;_: detecting_VBG tissue_NN specificity_NN for_IN a_DT previously_RB unknown_JJ alternative_NN splice_NN (_( in_IN a_DT known_VBN gene_NN or_CC in_IN a_DT novel_NN gene_NN )_) ._SENT Combining_VBG these_DT categories_NNS ,_, 78_CD %_NN (_( 29_CD /37_CD )_) of_IN our_PP$ brain-_NN and_CC muscle-specific_JJ alternative_JJ splices_NNS appear_VBP to_TO be_VB novel_JJ ._SENT It_PP seems_VBZ likely_RB that_IN our_PP$ database_NN can_MD be_VB a_DT valuable_JJ source_NN of_IN interesting_JJ discoveries_NNS for_IN biologists_NNS who_WP study_VBP these_DT genes_NNS ,_, as_RB well_RB as_IN researchers_NNS who_WP study_VBP tissue-specific_JJ regulation_NN of_IN splicing_VBG ._SENT Distribution_NN and_CC enrichment_NN of_IN tissue-specific_JJ alternative_NN splicing_VBG |_SYM We_PP analyzed_VBD the_DT distribution_NN of_IN tissue-specific_JJ alternative_NN splicing_VBG over_IN the_DT 46_CD human_JJ tissues_NNS in_IN our_PP$ classification_NN ._SENT We_PP identified_VBD tissue-specific_JJ alternative_NN splicing_VBG in_IN the_DT HC_NP group_NN for_IN 30_CD of_IN the_DT 46_CD human_JJ tissues_NNS ._SENT The_DT largest_JJS category_NN by_IN total_JJ number_NN of_IN tissue-specific_JJ splice_NN forms_NNS was_VBD brain_NN ,_, which_WDT represented_VBD 18_CD %_NN of_IN all_DT tissue-specific_JJ alternative_NN splicing_VBG events_NNS we_PP observed_VBD ._SENT The_DT tissues_NNS that_IN each_DT accounted_VBD for_IN at_IN least_JJS 4_CD %_NN of_IN observed_JJ tissue-specific_JJ forms_NNS were_VBD brain_NN ,_, eye_retina_NP ,_, lung_NN ,_, liver_NN ,_, pancreas_NN ,_, placenta_NN ,_, ovary_NN ,_, uterus_NN ,_, testis_NN ,_, lymph_NN ,_, muscle_NN and_CC skin_NN ._SENT This_DT is_VBZ consistent_JJ with_IN results_NNS from_IN a_DT survey_NN of_IN the_DT alternative_JJ exons_NNS from_IN the_DT published_VBN literature_NN ,_, in_IN which_WDT brain_NN and_CC neurons_NNS were_VBD ranked_VBD highest_JJS among_IN human_JJ tissues_NNS ._SENT Since_IN the_DT number_NN of_IN ESTs_NN sampled_VBN is_VBZ very_RB different_JJ for_IN each_DT tissue_NN ,_, we_PP have_VBP also_RB normalized_VBN the_DT rate_NN of_IN detection_NN of_IN tissue-specific_JJ alternative_JJ splices_NNS within_IN each_DT tissue_NN by_IN its_PP$ total_JJ number_NN of_IN ESTs_NN ._SENT We_PP defined_VBD the_DT enrichment_NN factor_NN (_( EF_NN )_) for_IN a_DT tissue_NN as_IN the_DT proportion_NN of_IN total_JJ tissue-specific_JJ alternative_NN splicing_VBG that_IN it_PP represents_VBZ divided_VBN by_IN the_DT proportion_NN of_IN total_JJ ESTs_NN that_IN it_PP represents_VBZ ._SENT Figure_NN compares_VBZ the_DT enrichment_NN factors_NNS for_IN our_PP$ classified_JJ human_JJ tissues_NNS ._SENT Skin_NN ,_, eye_retina_NN and_CC muscle_NN ranked_VBD highest_JJS (_( 2.4_CD times_NNS more_RBR tissue-specific_JJ splice_NN forms_NNS than_IN average_NN )_) ,_, with_IN lymph_NN (_( 2.0_CD )_) and_CC testis_NN next_JJ (_( 1.8_CD )_) ,_, followed_VBN by_IN brain_NN (_( 1.2_CD )_) and_CC liver_NN (_( 1.1_CD )_) ._SENT Other_JJ tissues_NNS with_IN above-average_JJ tissue_NN specificity_NN were_VBD bladder_NN ,_, mammary__JJ gland_NN and_CC pancreas_NN ._SENT Overall_RB ,_, this_DT is_VBZ consistent_JJ with_IN previous_JJ studies_NNS indicating_VBG the_DT immune_JJ and_CC nervous_JJ systems_NNS as_IN major_JJ loci_NNS of_IN alternative_NN splicing_VBG (_( ,_, )_) and_CC a_DT common_JJ focus_NN on_IN regulation_NN of_IN alternative_NN splicing_VBG in_IN neuronal_JJ tissues_NNS ._SENT It_PP is_VBZ also_RB striking_JJ that_IN at_IN the_DT high_JJ end_NN of_IN the_DT ranking_JJ ,_, more_RBR sharply_RB defined_VBN tissue_NN categories_NNS (_( e.g._FW retina_NN ,_, muscle_NN ,_, skin_NN ,_, lymph_NN )_) returned_VBD higher_JJR yields_NNS of_IN tissue_NN specificity_NN detection_NN than_IN broadly_RB defined_VBN categories_NNS such_JJ as_IN brain_NN ._SENT This_DT does_VBZ not_RB necessarily_RB mean_VB that_IN there_EX is_VBZ more_JJR tissue-specific_JJ alternative_NN splicing_VBG in_IN retina_NN or_CC muscle_NN than_IN in_IN the_DT many_JJ tissues_NNS in_IN the_DT brain_NN ._SENT Instead_RB ,_, it_PP may_MD simply_RB reflect_VB serious_JJ limitations_NNS in_IN the_DT nature_NN of_IN the_DT library_NN samples_NNS (_( that_DT most_JJS of_IN them_PP are_VBP grossly_RB defined_VBN ,_, combining_VBG all_PDT the_DT different_JJ tissues_NNS that_WDT compose_VBP an_DT entire_JJ organ_NN )_) and_CC of_IN our_PP$ TS_NP scoring_VBG calculation_NN ._SENT Bioinformatics_NP analysis_NN of_IN a_DT novel_JJ tissue-specific_JJ splice_NN form_NN |_SYM To_TO demonstrate_VB the_DT value_NN of_IN our_PP$ database_NN for_IN biological_JJ discovery_NN ,_, Figure_NP shows_VBZ our_PP$ analysis_NN of_IN a_DT representative_JJ example_NN (_( Hs.184592_NP )_) in_IN which_WDT we_PP detected_VBD a_DT novel_JJ kidney-specific_JJ alternative_NN splicing_VBG event_NN (_( TS_NP score_NN 94_CD )_) ._SENT As_IN part_NN of_IN our_PP$ genome-wide_JJ analysis_NN of_IN alternative_NN splicing_VBG ,_, we_PP generated_VBD predicted_VBN protein_NN isoforms_NNS and_CC analyzed_VBD their_PP$ domain_NN composition_NN by_IN searching_VBG against_IN protein_NN domain_NN databases_NNS ._SENT This_DT gene_NN encodes_VBZ a_DT serine_NN /threonine_NN protein_NN kinase_NN ,_, WNK1_NP (_( with_IN no_DT K_NN =_SYM lysine_NN )_) ,_, which_WDT has_VBZ only_RB recently_RB been_VBN described_VBN ._SENT This_DT gene_NN has_VBZ 28_CD exons_NNS and_CC encodes_VBZ a_DT huge_JJ protein_NN with_IN a_DT kinase_NN domain_NN near_IN its_PP$ N-terminus_NP and_CC two_CD coiled-coil_NN conserved_VBN domains_NNS ._SENT Its_PP$ name_NN refers_VBZ to_TO the_DT surprising_JJ replacement_NN of_IN an_DT active_JJ site_NN lysine_NN residue_NN with_IN a_DT cysteine_NN ,_, which_WDT leaves_VBZ kinase_NN activity_NN intact_JJ ._SENT Our_PP$ automated_JJ procedure_NN identified_VBD a_DT novel_JJ kidney-specific_JJ alternative_NN splicing_VBG event_NN between_IN exons_NNS IV_NP and_CC V_CD (_( Fig._NN B_NN )_) ._SENT For_IN the_DT isoform_NN we_PP detected_VBD outside_IN kidney_NN our_PP$ deduced_VBN protein_NN sequence_NN is_VBZ identical_JJ to_TO the_DT reported_VBN protein_NN sequence_NN ._SENT Exons_NNS IV_CD ,_, V_CD and_CC VI_NP encode_VBP the_DT second_JJ half_NN of_IN the_DT kinase_NN domain_NN of_IN this_DT enzyme_NN (_( Fig._NN C_NP )_) ._SENT In_IN the_DT kidney-specific_JJ isoform_NN exon_NN IV_NP is_VBZ replaced_VBN by_IN exon_NN IVa_NP ,_, drastically_RB altering_VBG the_DT protein_NN sequence_NN ._SENT It_PP contains_VBZ a_DT 63_CD nt_NNS upstream_IN in-frame_JJ stop_NN codon_NN (_( UGA_NP )_) ,_, as_RB well_RB as_IN a_DT subsequent_JJ start_NN codon_NN (_( AUG_NP )_) for_IN an_DT ORF_NP that_WDT extends_VBZ in-frame_NN into_IN the_DT rest_NN of_IN the_DT normal_JJ protein_NN sequence_NN in_IN exons_NNS V_CD onwards_RB ._SENT Thus_RB it_PP is_VBZ likely_JJ that_IN exon_NN IVa_NP encodes_VBZ an_DT alternative_JJ 30_CD amino_NN acid_JJ N-terminus_NN of_IN the_DT WNK1_NP protein_NN ,_, replacing_VBG 384_CD amino_NN acids_NNS of_IN the_DT usual_JJ WNK1_NP protein_NN N-terminus_NP ._SENT This_DT appears_VBZ to_TO disrupt_VB the_DT kinase_NN domain_NN and_CC to_TO eliminate_VB WNK1_JJ kinase_NN activity_NN specifically_RB in_IN kidney_NN ._SENT Our_PP$ data_NNS show_VBP eight_CD ESTs_NN aligning_VBG with_IN exon_NN IVa_NP and_CC extending_VBG up_RP to_TO 42_CD nt_NNS upstream_RB of_IN the_DT AUG_NP start_NN codon_NN ._SENT However_RB ,_, because_IN ESTs_NNS are_VBP short_JJ fragments_NNS ,_, in_IN this_DT case_NN they_PP do_VBP not_RB extend_VB to_TO a_DT 3_CD '_POS splice_NN site_NN and_CC thus_RB do_VBP not_RB show_VB where_WRB the_DT beginning_NN of_IN exon_NN IVa_NP might_MD be_VB ._SENT However_RB ,_, in_IN the_DT 21_CD nt_NN between_IN the_DT in-frame_JJ stop_NN codon_NN and_CC the_DT start_NN of_IN the_DT first_JJ EST_JJ alignment_NN there_EX is_VBZ no_DT consensus_NN 3_CD '_'' splice_NN site_NN (_( polypyrimidine_JJ tract_NN +_SYM AG_NP )_) ._SENT Thus_RB ,_, even_RB if_IN exon_NN IVa_NP is_VBZ spliced_VBN to_TO upstream_JJ exons_NNS ,_, the_DT in-frame_JJ stop_NN codon_NN would_MD evidently_RB be_VB included_VBN and_CC the_DT kinase_NN domain_NN would_MD be_VB removed_VBN from_IN the_DT WNK1_NP protein_NN product_NN ._SENT It_PP is_VBZ also_RB possible_JJ that_IN exon_NN IVa_NP represents_VBZ an_DT alternative_JJ promoter_NN site_NN ._SENT Although_IN this_DT is_VBZ a_DT novel_JJ discovery_NN ,_, there_EX is_VBZ experimental_JJ data_NNS that_WDT support_VBP it_PP ._SENT Previous_JJ studies_NNS of_IN the_DT expression_NN of_IN WNK1_NP have_VBP reported_VBN both_CC an_DT 11_CD --_: 12_CD kb_NN band_NN observed_VBD ubiquitously_RB in_IN many_JJ tissues_NNS and_CC a_DT 9.5_CD --_: 10_CD kb_NN band_NN expressed_VBN at_IN high_JJ level_NN in_IN the_DT kidney_NN (_( ,_, )_) ._SENT This_DT truncated_JJ transcript_NN is_VBZ consistent_JJ with_IN the_DT kidney-specific_JJ exon_NN IVa_NP alternative_JJ splice_NN that_IN we_PP have_VBP identified_VBN ,_, but_CC the_DT reported_VBN band_NN has_VBZ not_RB been_VBN further_RBR characterized_VBN ._SENT In_IN 7_CD --_: 10_CD ESTs_NN we_PP have_VBP also_RB detected_VBN alternative_NN splicing_VBG in_IN a_DT variety_NN of_IN tissues_NNS omitting_VBG exons_NNS IX_NP ,_, XI_NP and_CC /or_NP XII_NP (_( and_CC a_DT single_JJ EST_NN omitting_VBG exon_NN XXVI_NNS )_) in_IN WNK1_NP ._SENT Exons_NNS IX_CD ,_, XI_NP and_CC XII_NP have_VBP been_VBN independently_RB reported_VBN to_TO be_VB alternatively_RB spliced_VBD (_( ,_, )_) ._SENT Bioinformatics_NP analysis_NN of_IN a_DT known_VBN splice_NN variant_NN |_SYM To_TO illustrate_VB further_RBR the_DT value_NN of_IN our_PP$ database_NN ,_, Figure_NP shows_VBZ our_PP$ bioinformatics_NN analysis_NN for_IN CDC42_NP (_( cell_NN division_NN cycle_NN 42_CD )_) ._SENT Many_JJ studies_NNS of_IN this_DT gene_NN provide_VB insight_NN into_IN its_PP$ splicing_VBG and_CC isoforms_NNS (_( --_: )_) ._SENT CDC42_NP is_VBZ a_DT member_NN of_IN the_DT Rho_NP family_NN ,_, which_WDT is_VBZ a_DT group_NN of_IN small_JJ GTPases_NNS ._SENT CDC42_NP plays_VBZ multiple_JJ functional_JJ roles_NNS in_IN cell_NN regulation_NN ._SENT Our_PP$ automated_JJ analysis_NN detected_VBD an_DT alternative_JJ splice_NN in_IN CDC42_NP ,_, with_IN one_CD splice_NN form_NN showing_VBG brain_NN specificity_NN ._SENT Our_PP$ f_NN 